Please ensure Javascript is enabled for purposes of website accessibility

What Happened in the Stock Market Today

By Jim Crumly - Updated Oct 5, 2017 at 4:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

On another record day for Wall Street, Constellation Brands rose on earnings and a biotech IPO almost doubled.

Stocks made strong gains today, with the Dow Jones Industrial Average (^DJI 1.05%) and the S&P 500 (^GSPC 1.05%) closing at record levels.

Today's stock market

Index Percentage Change Point Change
Dow 0.50% 113.75
S&P 500 0.56% 14.33

Data source: Yahoo! Finance.

Technology stocks had a big day, with the Technology Select Sector SPDR ETF (XLK 0.23%) gaining 1%. Banks had another solid performance; the SPDR S&P Bank ETF (KBE 1.69%) was up 1.3%.

As for individual stocks, Constellation Brands (STZ 1.02%) rose on a strong quarter, and Rhythm Pharmaceuticals (RYTM 3.61%) shot higher on its first day of trading as a public company.

Rising stock graph.

Image source: Getty Images.

Constellation Brands brews a heady quarter

Constellation Brands reported a quarter that beat expectations for both sales and profit, and investors toasted the company by bidding up shares a cool 4%. Revenue grew 3% to $2.09 billion, and comparable earnings per share jumped 40% from last year's quarter to $2.47. The consensus analyst estimate was for earnings of $2.17 per share on revenue of $2.06 billion. The company also raised guidance for full-year comparable EPS to a range of $8.25 to $8.40, while analysts had been expecting $8.18.

Constellation's beer business continues to shine in an industry that isn't growing overall. Net sales for the beer division grew 12.8% and depletion volume -- the sales from distributors to retail locations -- increased 8.1%. Operating income from the division grew a surprising 25.6%, fueling the earnings beat. Organic sales for the wine and spirits division fell 0.9%, but depletions were up 5% and operating margin improved by 40 basis points.

"We remain the leader in the high-end of the U.S. beer market, and we are reaping the benefits of our Wine and Spirits premiumization efforts," said CEO Rob Sands in the press release.

Constellation has been gaining market share in the fastest-growing segment of the U.S. beer market, and is revamping its wine and spirits business by divesting underperforming labels and acquiring new brands. With a share price that's up over 36% this year, shareholders have had their thirst for gains well satisfied.

Rhythm Pharmaceuticals debuts with a bang

Shares of biotech Rhythm Pharmaceuticals skyrocketed on their first day of trading, almost doubling during the day but eventually falling back to close up 76.5%. The Boston-based specialist in ultra-rare metabolic diseases offered 7,050,000 shares at $17 per share; the stock opened at $23 and rose during the day to close at $30. After the offering, the company has 25.7 million shares outstanding for a market capitalization of $771 million. 

Rhythm is a clinical-stage biotech with no currently shipping drugs, but is working on a drug called setmelanotide to treat rare genetic disorders that cause patients to have intense and unrelenting feelings of hunger, leading to life-threatening obesity. The company is focusing on six diseases that arise from the genetic condition, and has demonstrated proof of concept in phase 2 trials for two of them, POMC deficiency obesity and LepR deficiency obesity. There are only 50 known patients in the world with POMC deficiency obesity, and the company estimates there are between 500 and 2,000 patients in the U.S. with LepR deficiency obesity. 

Rhythm emphasizes that it has no intention to address the broader issue of obesity, but is only looking at treatments for these very rare genetic disorders. Given the small patient populations involved and the likelihood that the company will not be filing a new drug application until 2019 at the earliest if the drug trials are successful, the valuation after today seems generous. But the market's embrace of the stock could be an indication of an increasingly receptive environment for biotech IPOs, and investors may be seeing more of these soon.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Constellation Brands, Inc. Stock Quote
Constellation Brands, Inc.
$235.43 (1.02%) $2.37
Rhythm Pharmaceuticals, Inc. Stock Quote
Rhythm Pharmaceuticals, Inc.
$4.30 (3.61%) $0.15
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
$31,097.26 (1.05%) $321.83
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
$3,825.33 (1.05%) $39.95
SPDR Series Trust - SPDR S&P Bank ETF Stock Quote
SPDR Series Trust - SPDR S&P Bank ETF
$44.62 (1.69%) $0.74
The Select Sector SPDR Trust - The Technology Select Sector SPDR Fund Stock Quote
The Select Sector SPDR Trust - The Technology Select Sector SPDR Fund
$127.41 (0.23%) $0.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.